In the third-line setting , for patients who have not received erlotinib or gefitinib , treatment with erlotinib is recommended .
There are insufficient data to recommend routine third-line cytotoxic therapy .
Purpose To provide evidence -based recommendations to up date the American Society of Clinical Oncology guideline on systemic therapy for stage IV non – small-cell lung cancer ( NSCLC ) .
Results This guideline up date reflects changes in evidence since the previous guideline .
The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer
The analyses of the retrospective data base of the International Association for the Study of Lung Cancer ( IASLC ) , consisting of more than 81,000 evaluable patients diagnosed with lung cancer between 1990 and 2000 , formed the basis of recommendations to the Union for International Cancer Control and the American Joint Committee on Cancer for the revision of the sixth edition of the tumor , node , and metastasis ( TNM ) classification of lung cancer . However , despite the large number of patients , not all descriptors could be vali date d. This prompted a new collection of retrospective and prospect i ve data to overcome the limitations of the original retrospective data base . The new IASLC data base has information on 94,708 new patients diagnosed of lung cancer between 1999 and 2010 . They originated from 35 sources in 16 countries , and 4,667 were su bmi tted via the online electronic data capture system . Europe contributed 46,560 patients , Asia : 41,705 , North America : 4,660 , Australia : 1,593 , and South America : 190 . After exclusions , 77,156 ( 70,967 with nonsmall cell lung cancer and 6,189 with small cell lung cancer ) remained for analysis . This data base will be analyzed according to established objectives for the T , the N , and the M components to inform the eighth edition of the TNM classification of lung cancer due to be published in 2016 . The IASLC hopes for the continuing contribution of our partners around the world to improve the classification of anatomical extent of disease , but also to create prognostic groups in a parallel project of the IASLC Staging and Prognostic Factors Committee
In the third-line setting , for patients who have not received erlotinib or gefitinib , treatment with erlotinib is recommended .
There are insufficient data to recommend routine third-line cytotoxic therapy .
Purpose To provide evidence -based recommendations to up date the American Society of Clinical Oncology guideline on systemic therapy for stage IV non – small-cell lung cancer ( NSCLC ) .
Results This guideline up date reflects changes in evidence since the previous guideline .